Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

Postal Realty Trust (PSTL) Q4 FFO Match Estimates
Postal Realty Trust (PSTL) Q4 FFO Match Estimates

Postal Realty Trust (PSTL) came out with quarterly funds from operations (FFO) of $0.33 per share, in line with the Zacks Consensus Estimate . This compares to FFO of $0.35 per share a year ago

MGE (MGEE) Meets Q4 Earnings Estimates
MGE (MGEE) Meets Q4 Earnings Estimates

MGE (MGEE) came out with quarterly earnings of $0.64 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.61 per share a year ago. These figures are adjusted for

Marqeta (MQ) Reports Break-Even Earnings for Q4
Marqeta (MQ) Reports Break-Even Earnings for Q4

Marqeta (MQ) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.01. This compares to a loss of $0.05 per share a year ago. These figures are

New Mountain Finance (NMFC) Q4 Earnings Meet Estimates
New Mountain Finance (NMFC) Q4 Earnings Meet Estimates

New Mountain Finance (NMFC) came out with quarterly earnings of $0.32 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.32 per share a year ago. These figures

Interparfums (IPAR) Beats Q4 Earnings and Revenue Estimates
Interparfums (IPAR) Beats Q4 Earnings and Revenue Estimates

Interparfums (IPAR) came out with quarterly earnings of $0.88 per share, beating the Zacks Consensus Estimate of $0.78 per share. This compares to earnings of $0.82 per share a year ago. These

Light & Wonder (LNWO) Surpasses Q4 Earnings Estimates
Light & Wonder (LNWO) Surpasses Q4 Earnings Estimates

Light & Wonder (LNWO) came out with quarterly earnings of $1.96 per share, beating the Zacks Consensus Estimate of $1.53 per share. This compares to earnings of $1.42 per share a year ago. These

Luxfer (LXFR) Beats Q4 Earnings Estimates
Luxfer (LXFR) Beats Q4 Earnings Estimates

Luxfer (LXFR) came out with quarterly earnings of $0.28 per share, beating the Zacks Consensus Estimate of $0.24 per share. This compares to earnings of $0.29 per share a year ago. These figures are

LTC Properties (LTC) Tops Q4 FFO Estimates
LTC Properties (LTC) Tops Q4 FFO Estimates

LTC Properties (LTC) came out with quarterly funds from operations (FFO) of $0.7 per share, beating the Zacks Consensus Estimate of $0.68 per share. This compares to FFO of $0.72 per share a year

Hyliion Holdings Corp. (HYLN) Reports Q4 Loss, Misses Revenue Estimates
Hyliion Holdings Corp. (HYLN) Reports Q4 Loss, Misses Revenue Estimates

Hyliion Holdings Corp. (HYLN) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to a loss of $0.08 per share a year ago. These

Globus Medical (GMED) Surpasses Q4 Earnings and Revenue Estimates
Globus Medical (GMED) Surpasses Q4 Earnings and Revenue Estimates

Globus Medical (GMED) came out with quarterly earnings of $1.28 per share, beating the Zacks Consensus Estimate of $1.06 per share. This compares to earnings of $0.84 per share a year ago. These

FrontView REIT, Inc. (FVR) Meets Q4 FFO Estimates
FrontView REIT, Inc. (FVR) Meets Q4 FFO Estimates

FrontView REIT, Inc. (FVR) came out with quarterly funds from operations (FFO) of $0.31 per share, in line with the Zacks Consensus Estimate . This compares to FFO of $0.27 per share a year ago

Flywire (FLYW) Reports Break-Even Earnings for Q4
Flywire (FLYW) Reports Break-Even Earnings for Q4

Flywire (FLYW) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.01. This compares to a loss of $0.12 per share a year ago. These figures are

Corcept Therapeutics (CORT) Q4 Earnings and Revenues Miss Estimates
Corcept Therapeutics (CORT) Q4 Earnings and Revenues Miss Estimates

Corcept Therapeutics (CORT) came out with quarterly earnings of $0.2 per share, missing the Zacks Consensus Estimate of $0.27 per share. This compares to earnings of $0.26 per share a year ago

Evolent Health (EVH) Q4 Earnings Top Estimates
Evolent Health (EVH) Q4 Earnings Top Estimates

Evolent Health (EVH) came out with quarterly earnings of $0.08 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to a loss of $0.02 per share a year ago. These

Everus Construction Group, Inc. (ECG) Q4 Earnings and Revenues Top Estimates
Everus Construction Group, Inc. (ECG) Q4 Earnings and Revenues Top Estimates

Everus Construction Group, Inc. (ECG) came out with quarterly earnings of $1.08 per share, beating the Zacks Consensus Estimate of $0.72 per share. This compares to earnings of $0.67 per share a

Carlyle Secured Lending, Inc. (CGBD) Q4 Earnings and Revenues Miss Estimates
Carlyle Secured Lending, Inc. (CGBD) Q4 Earnings and Revenues Miss Estimates

Carlyle Secured Lending, Inc. (CGBD) came out with quarterly earnings of $0.33 per share, missing the Zacks Consensus Estimate of $0.38 per share. This compares to earnings of $0.47 per share a year

AbCellera Biologics Inc. (ABCL) Reports Q4 Loss, Tops Revenue Estimates
AbCellera Biologics Inc. (ABCL) Reports Q4 Loss, Tops Revenue Estimates

AbCellera Biologics Inc. (ABCL) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to a loss of $0.11 per share a year ago. These

Archrock Inc. (AROC) Q4 Earnings and Revenues Beat Estimates
Archrock Inc. (AROC) Q4 Earnings and Revenues Beat Estimates

Archrock Inc. (AROC) came out with quarterly earnings of $0.69 per share, beating the Zacks Consensus Estimate of $0.4 per share. This compares to earnings of $0.35 per share a year ago. These

CeriBell, Inc. (CBLL) Reports Q4 Loss, Beats Revenue Estimates
CeriBell, Inc. (CBLL) Reports Q4 Loss, Beats Revenue Estimates

CeriBell, Inc. (CBLL) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to a loss of $0.4 per share a year ago. These figures

Slide Insurance Holdings, Inc. (SLDE) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
Slide Insurance Holdings, Inc. (SLDE) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

Slide Insurance Holdings, Inc. (SLDE) reported $347.01 million in revenue for the quarter ended December 2025, representing no change year over year. EPS of $1.23 for the same period compares to $0

Resideo Technologies (REZI) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
Resideo Technologies (REZI) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates

Resideo Technologies (REZI) reported $1.9 billion in revenue for the quarter ended December 2025, representing a year-over-year increase of 2%. EPS of $0.50 for the same period compares to $0.59 a

Merit Medical (MMSI) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
Merit Medical (MMSI) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

For the quarter ended December 2025, Merit Medical (MMSI) reported revenue of $393.94 million, up 10.9% over the same period last year. EPS came in at $1.04, compared to $0.93 in the year-ago

Compared to Estimates, Realty Income Corp. (O) Q4 Earnings: A Look at Key Metrics
Compared to Estimates, Realty Income Corp. (O) Q4 Earnings: A Look at Key Metrics

For the quarter ended December 2025, Realty Income Corp. (O) reported revenue of $1.49 billion, up 11% over the same period last year. EPS came in at $1.08, compared to $0.23 in the year-ago

Here's What Key Metrics Tell Us About Revolve Group (RVLV) Q4 Earnings
Here's What Key Metrics Tell Us About Revolve Group (RVLV) Q4 Earnings

For the quarter ended December 2025, Revolve Group (RVLV) reported revenue of $324.37 million, up 10.4% over the same period last year. EPS came in at $0.26, compared to $0.17 in the year-ago

Jazz (JAZZ) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
Jazz (JAZZ) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates

For the quarter ended December 2025, Jazz Pharmaceuticals (JAZZ) reported revenue of $1.2 billion, up 10.1% over the same period last year. EPS came in at $6.64, compared to $6.60 in the year-ago